New drug ALXN2030 takes first safety step in healthy volunteers
NCT ID NCT05501717
First seen Feb 20, 2026 · Last updated May 28, 2026 · Updated 10 times
Summary
This study is an early-stage trial to check if a single dose of ALXN2030 is safe and tolerable in healthy adults. About 48 participants will receive either the drug or a placebo. Researchers will monitor side effects and measure how the drug behaves in the body. This trial does not aim to treat any disease.
Disclaimer
Read more
Show less
This is a summary of
the original study
.
Summaries may miss details or leave out important information. Before applying or accepting participation, make sure you have read and understood the full study. Curemydisease.com takes no responsibility whatsoever for anything missed, misunderstood, or acted upon as a result of our summary — we know it does not capture everything.
This is a summary of the original study . Summaries may miss details or leave out important information. Before applying or accepting participation, make sure you have read and understood the full study. Curemydisease.com takes no responsibility whatsoever for anything missed, misunderstood, or acted upon as a result of our summary — we know it does not capture everything.
Get updates
Get notified about this study
Sign up to get updates when this study changes or when new studies for HEALTHY are added.
By submitting, you agree to our Terms of use
Contacts and locations
Show contact details
Enter your email to view the contact information for this study.
By submitting, you agree to our Terms of use
Locations
-
Research Site
Harrow, HA1 3UJ, United Kingdom
Conditions
Explore the condition pages connected to this study.